A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With a Prostate-specific Antigen Response
A prostate-specific antigen (PSA) response was defined as a PSA decline from Baseline of 50% or greater, repeated on 2 occasions at least 4 weeks apart.
Assessed monthly from Baseline until the end of study (up to 8 months)
No
United States: Food and Drug Administration
INCB 18424-254
NCT00638378
February 2008
January 2009
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Great Falls, Montana 59405 | |
Fountain Valley, California 92708 | |
Columbia, Missouri 65203 | |
Albany, New York 12208 | |
Philadelphia, Pennsylvania 19104 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
Kansas City, Kansas 66160 | |
Hackensack, New Jersey 07601 | |
Charleston, South Carolina | |
Bismarck, North Dakota 58501 |